NVS
Novartis AG
NYSE · Healthcare · Drug Manufacturers - General · CH
$159.68
−2.09%Year over year
Reported trailing growth
- Revenue
- +0.8%
- EBITDA
- -2.0%
- EBIT
- +1.8%
- EPS
- -3.5%
- Free cash flow
- -5.9%
- Operating cash flow
- -11.5%
Forward estimates
Based on analyst estimates
- Revenue
- +6.1%
- EBITDA
- +13.3%
- EPS
- +40.4%
Three-year CAGR
- Revenue
- +8.0%
- EBITDA
- +16.1%
- EBIT
- +29.0%
- Net income
- +26.4%
- EPS
- +31.5%
- Free cash flow
- +13.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026